HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SDZ GLC 756

a novel octahydrobenzoquinoline

Also Known As:

GLC 756; GLC-756; SDZ GLC-756

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - SDZ GLC 756: 3

Experts

1.	Court, M: 1 article (11/2005)
2.	Germann, P G: 1 article (11/2005)
3.	Laengle, U W: 1 article (11/2005)
4.	Markstein, R: 1 article (11/2005)
5.	Nogues, V: 1 article (11/2005)
6.	Roman, D: 1 article (11/2005)

Related Diseases

1.	Glaucoma 01/01/1996 - "The simultaneous D-1 antagonistic and D-2 agonistic properties of SDZ GLC-756 may provide a new pharmacological approach to the treatment of glaucoma, which deserves further investigation." 09/01/1995 - "The simultaneous D-1 antagonistic and D-2 agonistic properties of SDZ GLC-756 may provide a new pharmacologic approach to treating glaucoma and ocular hypertension, which deserves further investigation." 09/01/1995 - "The novel dopamine D-1 antagonist and D-2 agonist, SDZ GLC-756, lowers intraocular pressure in healthy human volunteers and in patients with glaucoma." 09/01/1995 - "In glaucoma patients the trial was designed as a crossover study administering SDZ GLC-756 (0.1%) eye drops and vehicle alone (control) to one eye in 12 patients with open-angle glaucoma or ocular hypertension. "
2.	Ocular Hypertension (Glaucoma, Suspect) 09/01/1995 - "The simultaneous D-1 antagonistic and D-2 agonistic properties of SDZ GLC-756 may provide a new pharmacologic approach to treating glaucoma and ocular hypertension, which deserves further investigation." 09/01/1995 - "To investigate the intraocular pressure (IOP)-reducing effect and side effects of SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, in control subjects and patients with open-angle glaucoma or ocular hypertension. " 09/01/1995 - "In glaucoma patients the trial was designed as a crossover study administering SDZ GLC-756 (0.1%) eye drops and vehicle alone (control) to one eye in 12 patients with open-angle glaucoma or ocular hypertension. "
3.	Open-Angle Glaucoma (Glaucoma, Open Angle) 09/01/1995 - "To investigate the intraocular pressure (IOP)-reducing effect and side effects of SDZ GLC-756, a novel dopamine D-1 antagonist and D-2 agonist, in control subjects and patients with open-angle glaucoma or ocular hypertension. " 09/01/1995 - "In glaucoma patients the trial was designed as a crossover study administering SDZ GLC-756 (0.1%) eye drops and vehicle alone (control) to one eye in 12 patients with open-angle glaucoma or ocular hypertension. "
4.	Uveitis 11/01/2005 - "GLC 756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, and timolol a beta-adrenoceptor antagonist using endotoxin-induced uveitis (EIU) and arthritis in rats as an in vivo model. "
5.	Arthritis (Polyarthritis) 11/01/2005 - "GLC 756, a novel mixed dopamine D2 receptor agonist and D1 receptor antagonist, and timolol a beta-adrenoceptor antagonist using endotoxin-induced uveitis (EIU) and arthritis in rats as an in vivo model. "

Related Drugs and Biologics

1.	Ophthalmic Solutions (Eye Drops)
2.	Dopamine D2 Receptors (Dopamine D2 Receptor)
3.	Timolol (Blocadren)
4.	Endotoxins
5.	Dopamine (Intropin)
6.	Adrenergic beta-Antagonists (beta-Adrenergic Blocking Agents)